U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

The global response to HIV has reached a crucial juncture. Groundbreaking scientific advances, including the development of ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Everyone who wants a new HIV shot* should be given it, according to Yvette Raphael, who chaired the Global Community Advisory Group for the large-scale clinical trials of the long-acting HIV treatment ...

A little over two decades ago, addressing Nigeria's HIV crisis topped U.S. President George W. Bush's priorities. Africa's ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on HIV's cone-shaped capsid protein, gets close, almost completely ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...